Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02247765
Other study ID # COVMOPR0445
Secondary ID
Status Completed
Phase N/A
First received September 18, 2014
Last updated December 2, 2014
Start date November 2014
Est. completion date December 2014

Study information

Verified date December 2014
Source Medtronic - MITG
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Observational

Clinical Trial Summary

To validate the proposed claims for pulse rate and saturation accuracy in a diverse subject population during motion over a specified saturation range.


Description:

Detailed description not required.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date December 2014
Est. primary completion date November 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Male or female of any race

- 18-50 years old, inclusive

- Females: negative urine pregnancy test on the day of study participation (prior to exposure to hypoxia)

- Completed within the last year: physical exam by a licensed physician, physician assistant (PA), or advanced practice nurse; including a 12 lead ECG, a medical history, and blood test (complete blood count and sickle cell trait/disease screening)

- Meets specific demographic requirements for the monitoring device under study

- Willing and able to provide written informed consent

- Able to participate for the duration of the evaluation

Exclusion Criteria:

- A room-air baseline % modulation < 1.5% on all four fingers on the test hand

- Under 18 years or over 50 years of age

- Pregnant and/or lactating women

- Hypertension: on three consecutive readings, systolic pressure greater than 145 mm Hg or diastolic pressure greater than 90 mm Hg

- Ventricular premature complexes (VPC's) that are symptomatic or occur at a rate of more than four per minute

- History of seizures (except childhood febrile seizures) or epilepsy

- History of unexplained syncope

- Daily or more frequent use of anxiolytic drugs (benzodiazepines) for treatment of anxiety disorder

- Recent history of frequent migraine headaches: average of two or more per month over the last year

- Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)

- History of acute altitude sickness at or below moderate elevation (up to 5,000-10,000 feet) defined as three or more of the following symptoms: moderate to severe headache, general malaise, dizziness/lightheadedness, nausea/vomiting, fatigue/weakness, shortness of breath, nosebleed, persistent rapid pulse, or peripheral edema

- History of significant respiratory disease such as severe asthma or emphysema or sleep apnea

- Sickle cell disease or trait

- Clinically significant abnormal finding on medical history, physical examination, clinical laboratory test or ECG. Clinical significance will be assessed by the principal investigator or study physician as designated.

- History of stroke, transient ischemic attack or carotid artery disease

- History of myocardial ischemia, angina, myocardial infarction, congestive heart failure or cardiomyopathy

- History of chronic renal impairment

- Severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors

- Unwillingness or inability to remove colored nail polish or artificial nails from test digit(s)

- Unwillingness or inability to give informed consent

- Prior or known allergies to: lidocaine (or similar pharmacological agents, e.g., Novocain) or heparin

- Recent arterial cannulation (i.e., less than 30 days prior to study date)

- Six or more arterial cannulations of each (right & left) radial artery

- History of clinically significant complications from previous arterial cannulation

- Current use of blood thinners: prescription or daily aspirin use

- History of bleeding disorders or personal history of prolonged bleeding from injury.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States Boulder Clinical Laboratory Boulder Colorado
United States Covidien RMS Boulder Colorado

Sponsors (1)

Lead Sponsor Collaborator
Medtronic - MITG

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary SpO2 Accuracy (percentage of blood oxygen saturation) SpO2 Accuracy (percentage of blood oxygen saturation) 1 hour No
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1